Clinical Trials Logo

Filter by:
NCT ID: NCT06083285 Completed - Clinical trials for To Explore the Influence of CRRT Nursing Team Management Plan on the Prognosis of SAKI Patients

Impact of the CRRT Management Protocol on Prognostic Outcome in Patients With Septic Acute Kidney Injury

Start date: February 1, 2021
Phase:
Study type: Observational

The implementation of CRRT nursing team management program in the treatment of SAKI can significantly reduce the incidence of adverse events and complications in CRRT nursing, which has a positive role in improving the success rate of CRRT treatment and the clinical outcome of patients.

NCT ID: NCT06083116 Completed - Diabetes in Adults Clinical Trials

Drug-Drug Interaction Study Between Henagliflozin Proline and Hydrochlorothiazide

Start date: August 28, 2019
Phase: Phase 1
Study type: Interventional

A single-center, single-arm, open-label, multi-dose, three-period study was conducted in healthy Chinese volunteers.

NCT ID: NCT06082986 Completed - Crohn Disease Clinical Trials

A Retrospective Observational Study of Ustekinumab Among Bio-naive Participants With Crohn's Disease in China

Start date: October 9, 2023
Phase:
Study type: Observational

Bio-naive participants are defined as the participants who previously have not received any biologics for Crohn's Disease (CD).The purpose of this retrospective study is to describe the endoscopic remission at week 24 among bio-naive participants with CD treated with ustekinumab in China.

NCT ID: NCT06082934 Recruiting - Clinical trials for Newly-diagnosed Ph+ Acute Lymphoblastic Leukemia

Olverembatinib Plus Venetoclax and Dexamethasone for Treatment-naïve Ph+ Acute Lymphoblastic Leukemia

Start date: November 1, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to explore the efficacy and safety of the OVD chemotherapy-free regimen (Olverembatinib, venetoclax and dexamethasone) in patients with newly-diagnosed Ph+ALL.

NCT ID: NCT06082843 Terminated - Liver Cirrhosis Clinical Trials

A Study to Test Whether Avenciguat Helps People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver) Who Had Bleeding in the Esophagus or Fluid Accumulation in the Belly

Start date: January 3, 2024
Phase: Phase 2
Study type: Interventional

This study is open to adults with advanced liver cirrhosis caused by hepatitis B, hepatitis C, alcohol-related liver disease, non-alcoholic steatohepatitis or other causes. People can join the study if they have high blood pressure in the portal vein (main vessel going to the liver) and bleeding in the esophagus or fluid accumulation in the belly. The purpose of this study is to find out whether a medicine called avenciguat helps people with this condition. Participants are put into 2 groups by chance. One group takes avenciguat tablets and the other group takes placebo tablets. Placebo tablets look like avenciguat tablets but do not contain any medicine. Participants take a tablet twice a day for 8 weeks. Participants are in the study for 2 to 3 months. During this time, they visit the study site regularly. At 2 of the visits, the doctors check the pressure in the liver vein by inserting a catheter (a long thin tube) that gives information about pressure in the portal vein. The change in blood pressure is then compared between the 2 groups to see whether the treatment works. The doctors also regularly check participants' health and take note of any unwanted effects.

NCT ID: NCT06082791 Recruiting - COPD Clinical Trials

A Clinical Validation Study to Evaluate the Diagnostic Accuracy of a Cough-based Auxiliary Diagnosis Algorithm for COPD

Start date: July 1, 2023
Phase:
Study type: Observational

Cough is one of the most common symptoms in COPD patients, and its different characteristics in amplitude, frequency and waveform can be analyzed by intelligent algorithms for the auxiliary diagnosis of COPD. The current study is to conduct external clinical validation of COPD auxiliary diagnosis algorithm and lung function prediction algorithm, and preliminatively verify the performance of the algorithm, with the ultimate goal of developing a portable and rapid COPD auxiliary diagnosis and condition assessment tool that can be used at home.

NCT ID: NCT06082765 Recruiting - Cervical Cancer Clinical Trials

Cervical Cancer Screening With NGS-HPV Technology Based on Menstrual Blood

Start date: September 1, 2021
Phase:
Study type: Observational

Our study is conducted to recruit cervical cancer screening patients to evaluate the application value of using high-throughput sequencing technology to detect HPV in menstrual blood for cervical cancer screening.

NCT ID: NCT06082648 Recruiting - Rectal Neoplasms Clinical Trials

Study of Brain-Gut Function Reconstruction After Intersphincteric Resection for Ultra-Low Rectal Tumors

Start date: June 1, 2023
Phase: N/A
Study type: Interventional

To investigate the effects of intersphincteric resection (ISR) of ultra-low rectal tumor on the brain-rectoanal function of patients, and to precisely localize the cerebral functional regulatory regions for intervention targets of anorectal remodeling. Utilizing transcranial magnetic stimulation(TMS) technology to explore the functional remodeling of the "new" anorectal muscle groups and provide a theoretical basis for more research on the rehabilitation and mechanism of fecal incontinence.

NCT ID: NCT06082635 Recruiting - Clinical trials for Non Small Cell Lung Cancer

TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)

Start date: December 14, 2023
Phase: Phase 3
Study type: Interventional

This is a multi-center, randomized, open-label, Phase III clinical trial which compares the safety and efficacy of TGRX-326 with crizotinib in patients with ALK-positive advanced or metastatic NSCLC

NCT ID: NCT06082596 Completed - Clinical trials for Relapsed or Refractory Multiple Myeloma

Study of BEBT-908 in Subjects With Advanced Hematological Tumors

Start date: March 2, 2016
Phase: Phase 1
Study type: Interventional

The purpose of this study was to evaluate the safety and tolerance of BEBT-908 for injection in the treatment of recurrent refractory malignant lymphoma, multiple myeloma and chronic lymphoblastic leukemia, and to obtain the pharmacokinetic data and preliminary efficacy of BEBT-908 for injection, and to explore the relationship between the safety and efficacy of BEBT-908 for injection and related biomarkers.